Cftr Trikafta denied for failing step therapy by Humana?

Humana's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Step Therapy to Trikafta — and Why You Can Challenge It

Humana's benefit design may require that a patient try one or more other CFTR modulators before approving Trikafta (elexacaftor/tezacaftor/ivacaftor). This is called step therapy or "fail first." For patients with cystic fibrosis (CF), step-therapy requirements on CFTR modulators can conflict directly with the FDA-approved indication and with guidance from the Cystic Fibrosis Foundation — making them among the most successfully overturned denial types.

## Why This Denial Happens

Step-therapy protocols are cost-containment tools built into formulary design. They are applied by algorithm at adjudication and do not account for individual clinical history or CFTR mutation profile. Trikafta is approved for a broader mutation population than earlier-generation modulators, so a generic step-therapy ladder may be clinically inapplicable.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 or state law within the timeframe on the denial letter (commonly 180 days). Request the specific step-therapy criteria being applied.
• External review (ACA §2719): After exhausting internal appeal — or concurrent with it in urgent cases — you may request independent external review. The reviewer applies evidence-based medical standards, not Humana's formulary hierarchy.
• Step-therapy override laws: Many states require insurers to grant step-therapy exceptions when prior therapy is contraindicated, clinically inappropriate, or when the patient has already tried and failed prior steps. Check whether your plan is state-regulated and cite the applicable statute in your appeal.
• Expedited track: Available within 72 hours when delay would seriously jeopardize health.
• Four-month window: External review requests are generally due within approximately four months of final internal denial — verify the exact date on your letter.

## Documentation to Gather

1. Diagnosis and mutation confirmation — chart notes and genetic testing confirming the specific CFTR mutation(s) and that the mutation class is covered by Trikafta's FDA-approved labeling. 2. Mutation-based inapplicability — a prescriber letter explaining why earlier-generation modulators are not indicated for this patient's specific mutation profile, citing the FDA label. 3. Prior treatment history — if any prior CFTR-modulator therapy was tried, document dates, duration, clinical response, and reason for discontinuation. 4. Medical-necessity letter — CF specialist's statement that initiating Trikafta directly is consistent with the Cystic Fibrosis Foundation care guidelines and with standard of care. 5. Clinical severity data — recent lung function measurements, exacerbation history, and nutritional status from the chart.

## Criteria-Mapping Structure

Obtain Humana's published step-therapy policy for CFTR modulators and the FDA prescribing label for Trikafta. Build a point-by-point table:

| Step-Therapy Requirement | How Your Case Satisfies or Bypasses It | |---|---| | Each prior-step drug listed in Humana's policy | Chart evidence of trial/failure OR prescriber attestation that the step is medically inapplicable | | FDA mutation-class indication | Documented mutation type | | Guideline alignment | CFF guideline citation from prescriber letter |

A well-structured table response substantially increases the likelihood of reversal at internal review and gives the external reviewer a clear basis for an override.